Bridget Wagner

Dr. Bridget Wagner


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
EDErcument Dirice
Ercument Dirice
DWDeepika Walpita
Deepika Walpita
AVAmedeo Vetere
Amedeo Vetere
BMBennett C. Meier
Bennett C. Meier
SKSevim Kahraman
Sevim Kahraman
BWBridget Wagner
Bridget Wagner
Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation–regulated kinase (DYRK) and cell division cycle–like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle–related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.

30 April 2012 in ACS Chemical Biology
Verified
Journal Article
Open access
YYYuan Yuan
Yuan Yuan
QWQiu Wang
Qiu Wang
JPJoshiawa Paulk
Joshiawa Paulk
SKStefan Kubicek
Stefan Kubicek
MKMelissa M. Kemp
Melissa M. Kemp
SSStuart L. Schreiber
Stuart L. Schreiber
Post-translational modifications of histones alter chromatin structure and play key roles in gene expression and specification of cell states. Small molecules that target chromatin-modifying enzymes selectively are useful as probes and have promise as therapeutics, although very few are currently available. G9a (also named euchromatin histone methyltransferase 2 (EHMT2)) catalyzes methylation of lysine 9 on histone H3 (H3K9), a modification linked to aberrant silencing of tumor-suppressor genes, among others. Here, we report the discovery of a novel histone methyltransferase inhibitor, BRD4770. This compound reduced cellular levels of di- and trimethylated H3K9 without inducing apoptosis, induced senescence, and inhibited both anchorage-dependent and -independent proliferation in the pancreatic cancer cell line PANC-1. ATM-pathway activation, caused by either genetic or small-molecule inhibition of G9a, may mediate BRD4770-induced cell senescence. BRD4770 may be a useful tool to study G9a and its role in senescence and cancer cell biology.

8 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NMNikita Moshkov
Nikita Moshkov
TBTim Becker
Tim Becker
KYKevin Yang
Kevin Yang
PHPeter Horvath
Peter Horvath
VDVlado Dancik
Vlado Dancik
JCJuan C. Caicedo
Juan C. Caicedo
Predicting assay results for compounds virtually using chemical structures and phenotypic profiles has the potential to reduce the time and resources of screens for drug discovery. Here, we evaluate the relative strength of three high-throughput data sources—chemical structures, imaging (Cell Painting), and gene-expression profiles (L1000)—to predict compound bioactivity using a historical collection of 16,170 compounds tested in 270 assays for a total of 585,439 readouts. All three data modalities can predict compound activity for 6–10% of assays, and in combination they predict 21% of assays with high accuracy, which is a 2 to 3 times higher success rate than using a single modality alone. In practice, the accuracy of predictors could be lower and still be useful, increasing the assays that can be predicted from 37% with chemical structures alone up to 64% when combined with phenotypic data. Our study shows that unbiased phenotypic profiling can be leveraged to enhance compound bioactivity prediction to accelerate the early stages of the drug-discovery process.

1 January 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
BWBridget Wagner
Bridget Wagner
SSStuart L. Schreiber
Stuart L. Schreiber

27 June 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YYY Yuan
Y Yuan
ATA J Tang
A J Tang
ACA B Castoreno
A B Castoreno
SKS-Y Kuo
S-Y Kuo
QWQ Wang
Q Wang
BWBridget Wagner
Bridget Wagner
The histone methyltransferase G9a is overexpressed in a variety of cancer types, including pancreatic adenocarcinoma, and promotes tumor invasiveness and metastasis. We recently reported the discovery of BRD4770, a small-molecule inhibitor of G9a that induces senescence in PANC-1 cells. We observed that the cytotoxic effects of BRD4770 were dependent on genetic background, with cell lines lacking functional p53 being relatively resistant to compound treatment. To understand the mechanism of genetic selectivity, we used two complementary screening approaches to identify enhancers of BRD4770. The natural product and putative BH3 mimetic gossypol enhanced the cytotoxicity of BRD4770 in a synergistic manner in p53-mutant PANC-1 cells but not in immortalized non-tumorigenic pancreatic cells. The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3 (B-cell lymphoma 2 19-kDa interacting protein)-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells.

1 June 2012 in Chemistry & Biology
Verified
Journal Article
Closed access
DCDanny Hung-Chieh Chou
Danny Hung-Chieh Chou
EHEdward B. Holson
Edward B. Holson
FWFlorence F. Wagner
Florence F. Wagner
ATAlicia J. Tang
Alicia J. Tang
RMRebecca L. Maglathlin
Rebecca L. Maglathlin
BWBridget Wagner
Bridget Wagner